ストックスクリーナーアプリを入手
746.54
0.94%
6.97
前日終値:
$739.57
開ける：
$737.2
24時間の取引高:
466.00K
Relative Volume:
0.63
時価総額：
$76.86B
収益：
$14.92B
当期純損益:
$4.42B
株価収益率:
18.19
EPS:
41.0422
ネットキャッシュフロー:
$3.79B
1週間 パフォーマンス:
+1.54%
1か月 パフォーマンス:
-7.57%
6か月 パフォーマンス:
-2.78%
1年 パフォーマンス:
+30.99%
1日の値動き範囲:
$732.83
$751.27
1週間の範囲:
$722.02
$753.68
52週間の値動き範囲:
$541.00
$859.34
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
名前
Regeneron Pharmaceuticals Inc
セクター
電話
(914) 847-7000
住所
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
825.03 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-31 | 再開されました | Piper Sandler | Overweight |
| 2026-03-06 | 開始されました | Barclays | Overweight |
| 2026-01-07 | アップグレード | BofA Securities | Underperform → Buy |
| 2025-12-03 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | 開始されました | HSBC Securities | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Perform |
| 2025-08-14 | 開始されました | Rothschild & Co Redburn | Buy |
| 2025-06-30 | ダウングレード | Argus | Buy → Hold |
| 2025-05-30 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | アップグレード | Citigroup | Neutral → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-02-05 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | ダウングレード | UBS | Buy → Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-09-24 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 開始されました | Bernstein | Outperform |
| 2024-01-12 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-03 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 繰り返されました | Oppenheimer | Perform |
| 2023-06-28 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | アップグレード | Jefferies | Hold → Buy |
| 2023-03-23 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | アップグレード | Cowen | Market Perform → Outperform |
| 2023-01-20 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-10-26 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-09-09 | アップグレード | Jefferies | Underperform → Hold |
| 2022-09-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 開始されました | Jefferies | Underperform |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-01-05 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-01-03 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 再開されました | Wells Fargo | Overweight |
| 2021-12-07 | 再開されました | Cowen | Market Perform |
| 2021-12-06 | 開始されました | Goldman | Buy |
| 2021-11-19 | 再開されました | BMO Capital Markets | Outperform |
| 2021-11-05 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-01-25 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-01-08 | アップグレード | Citigroup | Neutral → Buy |
| 2020-10-05 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2020-07-09 | アップグレード | SunTrust | Hold → Buy |
| 2020-05-26 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-04-17 | アップグレード | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 開始されました | The Benchmark Company | Hold |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-02-26 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | アップグレード | Jefferies | Hold → Buy |
| 2020-02-11 | アップグレード | Argus | Hold → Buy |
| 2019-12-24 | 開始されました | Raymond James | Mkt Perform |
| 2019-12-16 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-12-13 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 開始されました | SunTrust | Hold |
| 2019-11-07 | アップグレード | Citigroup | Neutral → Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
すべてを表示
Regeneron Pharmaceuticals Inc (REGN) 最新ニュース
Sanofi Puts Up $1B to Expand Regeneron Alliance and Develop Next-Gen Dupixent - MedCity News
Baird reiterates Regeneron stock rating on Sanofi collaboration By Investing.com - Investing.com Canada
Sanofi To Pay Regeneron Up To $8B In Immunology Alliance - Law360
REGN Maintained by Jefferies -- Price Target Raised to $930 - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $930.00 - MarketBeat
Sanofi Commits Up to $8 Billion to Expand Regeneron Alliance on Next-Gen Antibodies - finance.biggo.com
Regeneron stock after-hours at EUR 660.45: minus 1.31 percent versus prior close - AD HOC NEWS
Jefferies raises Regeneron stock price target to $930 on partnership By Investing.com - Investing.com Canada
Regeneron Pharmaceuticals (REGN) Reports Promising Ubamatamab Tr - GuruFocus
Regeneron And Sanofi Announce A Win-Win Collaboration Expansion (NASDAQ:REGN) - Seeking Alpha
Regeneron Pharmaceuticals (REGN) Reports Promising Phase 1/2 Tri - GuruFocus
Why Regeneron (REGN) Stock Is Trading Lower Today - FinancialContent
Regeneron posts trial data for ovarian cancer therapy (REGN:NASDAQ) - Seeking Alpha
Regeneron Pharmaceuticals (REGN) Unveils Positive Phase 2 COURAG - GuruFocus
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool
Sanofi and Regeneron expand global alliance - The Pharma Letter
Regeneron Pharmaceuticals Says Ubamatamab Show 73% Objective Response Rate & 11-Month Median PFS In LGSOC Patients - TradingView
Sanofi to ‘ignite’ R&D in $8B deal with longstanding partner Regeneron - BioWorld News
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC) - The Manila Times
Regeneron reports 73% response rate for ovarian cancer drug trial By Investing.com - Investing.com Canada
Sanofi, Regeneron broaden alliance to find their next Dupixent - Yahoo Finance
Patients in a small study had a median 11 months without ovarian cancer worsening on an experimental drug. - Stock Titan
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss - marketscreener.com
Sanofi, Regeneron to Expand Alliance in Up to $8 Billion Deal - WSJ
BMO reiterates Regeneron stock Outperform on Sanofi deal expansion By Investing.com - Investing.com Canada
Sanofi Deepens 20-Year Drug Development Pact With Regeneron, Pledges Up to $8 Billion - Benzinga
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion - MarketBeat
REGN: Expanded alliance targets next-gen type 2 medicines with equal cost/profit sharing and $8B in payments - TradingView
REGN Upgraded by Argus Research -- Price Target Announced at $85 - GuruFocus
Argus upgrades Regeneron stock to Buy with USD 850 target - AD HOC NEWS
Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor - biospace.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Argus - MarketBeat
Upcoming Webinar Hosted by Xtalks: Inside Regeneron's Path to Scientific Intelligence and R&D Efficiency - PR Newswire
Regeneron Pharmaceuticals, Inc. (REGN) Stock Forecasts - Yahoo Finance
Argus upgrades Regeneron stock rating to buy on Dupixent growth By Investing.com - Investing.com Canada
BreakingviewsCOMMENTARY: Sanofi’s Regeneron fix requires extra shot of M&A - reuters.com
Regeneron Pharmaceuticals, Inc. (REGN) Stock Price, News, Quote & History - Yahoo Finance
Sanofi and Regeneron expand immunology partnership to the tune of $8bn - Pharmaceutical Technology
Sanofi to invest up to $8bn to expand alliance with Regeneron - marketscreener.com
REGN Stock In Focus: Sanofi Expands Immunology Deal With $1B Upfront Payment And 4 New Antibodies - Stocktwits
Sanofi expands Regeneron partnership with up to $8 billion deal i - Global Banking & Finance Review
Sanofi Expands Collaboration with Regeneron in Immunology with $10 Billion Upfront Payment - GuruFocus
Regeneron, Sanofi expand alliance with $1 billion upfront deal By Investing.com - Investing.com Canada
Regeneron drug said to cut muscle loss when combined with Novo's semaglutide (REGN:NASDAQ) - Seeking Alpha
Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion - Yahoo Finance
Sanofi and Regeneron Expand Antibody Collaboration - marketscreener.com
Sanofi, Regeneron expand tie-up with $8 billion drug-development deal, settle legal dispute - marketscreener.com
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies - The Manila Times
Regeneron and Sanofi Expand Long-Standing Collaboration to Add Next-Generation Long-Acting Immunology Antibodies in Deal Worth Up to $8 Billion - Quiver Quantitative
REGN: Expanded partnership targets next-gen immunology therapies, sharing costs, profits, and innovation - TradingView
Regeneron (REGN) Grants One-Time Performance Awards to CEO and CSO, Forms New Subsidiary - GuruFocus
Regeneron Pharmaceuticals Inc (REGN) 財務データ
収益
当期純利益
現金流量
EPS
Regeneron Pharmaceuticals Inc (REGN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| McCourt Marion | EVP Commercial |
Sep 03 '26 |
Sale |
857.39 |
1,131 |
969,708 |
12,003 |
| Guarini Kathryn | Director |
Sep 02 '26 |
Option Exercise |
719.37 |
400 |
287,748 |
1,003 |
| Guarini Kathryn | Director |
Sep 02 '26 |
Sale |
850.00 |
400 |
340,000 |
603 |
14.21%
大文字化:
|
ボリューム (24 時間):